Amyloid beta-peptide (AB) accumulation and toxicity in the brain are central events in the pathogenesis of Alzheimer's disease (AD). The low-density lipoprotein receptor-related protein (LRP) interacts with beta-amyloid-precursor protein (APP) and regulates its endocytic trafficking and processing to AB. LRP is also a major receptor in the brain for apolipoprotein E (apoE), which modulates AB clearance, cholesterol metabolism, and cellular signaling. Previous studies have detected abundant functional soluble LRP (sLRP) in peripheral and our preliminary work has detected sLRP in human brain and cerebral spinal fluid (CSF). Molecular and cellular studies have defined Notch/APP-like sequential processing of LRP by matrix metalloprotease (MMP) and by b- and g-secretases. Our long-term goal is to understand how LRP proteolysis is regulated in the brain and dysregulated in AD, and how these proteolytic events and processing products impact its function in apoE metabolism and signaling, as well as APP trafficking and processing to AB. Our preliminary studies have shown that a g-secretase cleavage product, APP intracellular domain (AICD), regulates LRP expression and function by directly binding to LRP promoter. Our studies also identified a novel adaptor protein, sorting nexin 17 (SNX17), that modulates endocytic trafficking and processing of both LRP and APP. Our central hypothesis is that LRP and APP proteolytic processing is dysregulated in AD by pathological ligands and trafficking events, and that this in turn impairs LRP expression and function in apoE metabolism and signaling in the brain. We propose four specific aims to test our hypothesis: 1) to identify LRP shedding enzymes and examine the functional impact of altered LRP shedding on apoE metabolism and signaling; 2) to examine how LRP expression, shedding, and proteolysis are altered in AD mouse models and during aging and AD in humans; 3) to study how APP processing products and other g-secretase cleavage events regulate LRP expression and function; and 4) to analyze how altered endocytic trafficking of LRP and APP by neuronal adaptor proteins influences their proteolytic processing, apoE metabolism and AB production. Together, these studies should allow us to define the mechanism and regulation of LRP expression, processing and function in the brain during aging and AD. Our proposed studies may also identify novel targets for AD diagnosis and therapy.

Public Health Relevance

The major objective of our proposal is to understand how an apoE receptor LRP undergoes proteolytic processing and how these cellular events are regulated in the brain. Because apoE is a major risk factor for Alzheimer's disease, a leading cause of dementia in elderly, our results may provide knowledge for diagnosis and/or therapy for Alzheimer's disease. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG031784-01
Application #
7435705
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Petanceska, Suzana
Project Start
2008-04-01
Project End
2013-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
1
Fiscal Year
2008
Total Cost
$311,600
Indirect Cost
Name
Washington University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Liu, Chia-Chen; Hu, Jin; Tsai, Chih-Wei et al. (2015) Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. J Neurosci 35:5851-9
Liu, Chia-Chen; Tsai, Chih-Wei; Deak, Ferenc et al. (2014) Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron 84:63-77
Medway, Christopher W; Abdul-Hay, Samer; Mims, Tynickwa et al. (2014) ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener 9:11
Zhao, Jing; Fu, Yuan; Liu, Chia-Chen et al. (2014) Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem 289:11282-92
Kanekiyo, Takahisa; Xu, Huaxi; Bu, Guojun (2014) ApoE and A? in Alzheimer's disease: accidental encounters or partners? Neuron 81:740-54
Liu, Chia-Chen; Liu, Chia-Chan; Kanekiyo, Takahisa et al. (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106-18
Holtzman, David M; Herz, Joachim; Bu, Guojun (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006312
Kanekiyo, Takahisa; Liu, Chia-Chen; Shinohara, Mitsuru et al. (2012) LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-ýý. J Neurosci 32:16458-65
Kanekiyo, Takahisa; Zhang, Juan; Liu, Qiang et al. (2011) Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci 31:1644-51
Li, Yonghe; Lu, Wenyan; King, Taj D et al. (2010) Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation. PLoS One 5:e11014

Showing the most recent 10 out of 18 publications